Skip to main navigation Skip to search Skip to main content

Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial

  • Eric L. Simpson
  • , Jonathan I. Silverberg
  • , Jacob P. Thyssen
  • , Manuelle Viguier
  • , Diamant Thaçi
  • , Marjolein de Bruin-Weller
  • , Stephan Weidinger
  • , Gary Chan
  • , Marco DiBonaventura
  • , Pinaki Biswas
  • , Claire Feeney
  • , Christopher Koulias*
  • , Michael J. Cork
  • *Corresponding author for this work
  • Oregon Health & Science University
  • Washington University in St. Louis
  • Copenhagen University Hospital Bispebjerg
  • Reims University Hospital
  • Utrecht University
  • University of Kiel
  • Pfizer Inc.
  • Pfizer Endocrine Care Europe
  • University of Sheffield

Fingerprint

Dive into the research topics of 'Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science